- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Is Abatacept effective in preventing type 1 diabetes in at-risk individuals? Phase 2 trial provides insights
![Is Abatacept effective in preventing type 1 diabetes in at-risk individuals? Phase 2 trial provides insights Is Abatacept effective in preventing type 1 diabetes in at-risk individuals? Phase 2 trial provides insights](https://medicaldialogues.in/h-upload/2023/01/16/750x450_198343-type-1-diabetes-1.webp)
USA: Results from a phase 2 clinical trial indicate that abatacept use did not significantly delay the progression to abnormal glucose intolerance of diabetes in at-risk individuals but did impact immune cell subsets and preserved insulin secretion. This provides additional insight into the effects of costimulation blockade on the progression of type 1 diabetes.
The trial provided new insight into the effects of abatacept use for delaying or preventing the progression of type 1 diabetes (T1D). The trial, whose findings were published in Diabetes Care, comprised more than stage 1 relatives at risk of T1D.
Previous studies have reported that inhibiting lymphocyte costimulation reduces β-cell function in people newly diagnosed with type 1 diabetes. William E. Russell, Vanderbilt University Medical Center, Nashville, TN, and colleagues tested whether abatacept would prevent or delay the progression of type 1 diabetes from normal glucose tolerance (NGT) to abnormal glucose tolerance (AGT) or diabetes and the effects of treatment on metabolic and immune responses.
For this purpose, they conducted a phase 2, placebo-controlled, randomized, double-masked trial of abatacept in antibody-positive participants with NGT who received monthly abatacept/placebo infusions for 12 months. The endpoint was abnormal glucose tolerance or diabetes, evaluated by oral glucose tolerance tests.
The study led to the following findings:
- A total of 101 participants received abatacept and 111 placebo. Of these, 81 (35 abatacept and 46 placebo) met the endpoint of AGT or type 1 diabetes diagnosis (hazard ratio 0.702).
- The C-peptide responses to oral glucose tolerance tests were higher in the abatacept arm.
- Abatacept reduced the frequency of inducible T-cell costimulatory (ICOS)+ PD1+ Tfh (T-follicular helper cells) during treatment, raised naïve CD4+ T cells, and also decreased the frequency of CD4+ regulatory T cells (Tregs) from the baseline.
- Twelve months after treatment, the frequency of ICOS+ Tfh, Tregs, and naïve CD4+ T cells returned to baseline.
“This trial of 1 year of abatacept treatment in people with stage 1 type 1 diabetes did demonstrate a statistically remarkable effect on advancing to stage 2 or stage 3 type 1 diabetes. In these early-stage participants, the treatment caused an effect on metabolic function and anticipated biologic changes in immune cells,” wrote investigators.
“Had there been higher progression rates in the placebo group or a longer treatment period, we may have observed a greater effect on metabolic function and a statistically significant effect on the primary outcome.”
They concluded, "the findings suggest that costimulation blockade may modify the progression of type 1 diabetes."
Reference:
William E. Russell, Brian N. Bundy, Mark S. Anderson, Laura A. Cooney, Stephen E. Gitelman, Robin S. Goland, Peter A. Gottlieb, Carla J. Greenbaum, Michael J. Haller, Jeffrey P. Krischer, Ingrid M. Libman, Peter S. Linsley, S. Alice Long, Sandra M. Lord, Daniel J. Moore, Wayne V. Moore, Antoinette M. Moran, Andrew B. Muir, Philip Raskin, Jay S. Skyler, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, Anette-Gabriele Ziegler, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group; Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023; dc222200. https://doi.org/10.2337/dc22-2200
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751